Compare AbCellera Biologics Inc (ABCL) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Atlassian Corporation PLC — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Atlassian Corporation PLC trades at $86.12 (market cap $22.43B). The key difference: Atlassian Corporation PLC is far larger — about 9.5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| ABCL | TEAM | |
|---|---|---|
Market Cap | $2.35B | $22.43B |
Sector | Health | Technology |
52-Week High | $8.12 | $220.89 |
52-Week Low | $2.78 | $57.15 |
Enterprise Value | $1.99B | $22.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Atlassian (TEAM) trades at $88.39, up 5.43% with bullish technical signals despite negative profitability metrics. The stock shows strong revenue growth from $2.8B in 2022 to $5.2B in 2025, though net losses persist. Recent earnings beats and cloud revenue momentum of 29% in Q3 FY26 support optimism. Analyst consensus is strongly bullish with 30 buy ratings and a $120.29 price target, representing 36% upside potential.
The outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent losses, high valuation multiples, and competitive pressures. With improving margins and strong institutional support, TEAM offers growth exposure but requires tolerance for current unprofitability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
